Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?
about
Which health technologies should be funded? A prioritization framework based explicitly on value for moneyFinancing prevention: opportunities for economic analysis across the translational research cycleExtended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial.Using cost-effectiveness estimates from survey data to guide commissioning: an application to home care.Cost-effectiveness analysis of guidelines for antihypertensive care in FinlandCost-effectiveness of an intervention to reduce emergency re-admissions to hospital among older patients.Economics notes: types of economic evaluationDevelopment of WHO guidelines on generalized cost-effectiveness analysis.Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 GroupThe German method for setting ceiling prices for drugs: in some cases less data are required.Building Efficient Crime Prevention Strategies: Considering the Economics of Investing in Human Development.Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility spaceValue-based medicine: concepts and applicationEfficient and equitable HIV prevention: A case study of male circumcision in South AfricaCost-effectiveness analysis and policy choices: investing in health systems.Setting priorities for the health care sector in Zimbabwe using cost-effectiveness analysis and estimates of the burden of disease.Evaluating willingness-to-pay thresholds for dementia caregiving interventions: application to the tailored activity program.Can cost-effectiveness analysis integrate concerns for equity? Systematic review.Lean systems approaches to health technology assessment: a patient-focused alternative to cost-effectiveness analysis.Rethinking cost-effectiveness in the era of zero healthcare spending growth.Are vaccination sites in Bangladesh scale efficient?Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?The HAART side of resource allocation.Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension.The practical impact of pharmacoeconomics on institutional managers.When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care.On the margins of health economics: a response to 'resolving NICE'S nasty dilemma'.Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problemInternal validation of models with several interventions.Reconsidering value for money in periodontal treatment.Allocation of resources between smoking cessation methods and lovastatin treatment of hypercholesterolaemia: based on cost effectiveness and the social welfare function.Uncertainty and the decision maker: assessing and managing the risk of undesirable outcomes.The changing role of economic evaluation in valuing medical technologies.Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study.Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor.Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules.Can the real opportunity cost stand up: displaced services, the straw man outside the room.Willingness to pay: a valid and reliable measure of health state preference?An empirical note on willingness to pay and starting-point bias.Where are we now in British health economics?
P2860
Q21195870-2F1BF06C-E5E0-4567-99C5-FE4427C97D3CQ28077941-61425AC3-0CAA-49A5-BC7F-41DB8623A92BQ30382239-7C8644AA-C8B2-47B4-8DB8-D2226B0FADDCQ30667017-4A123257-FE2B-4ECC-8F44-8BDAD9C600DEQ33303769-DD761BF9-E040-4C04-9F6D-6C2BBC462867Q33510685-C9E077DA-4EC3-461D-B954-B07574B63E6AQ33633515-C6498E9C-E5FD-4562-A6CC-FE2B4278D80DQ33903387-048AEF95-6737-412E-B3DE-A1E194DA8A4DQ33954107-010A4635-3B02-4643-882F-2320247630C4Q33989344-E8622780-4331-4C75-9409-7A75F32E59DBQ34065635-CA643624-3096-4032-8193-640BDBBD8FB8Q35159488-A2E35B44-B706-4D01-BE8C-5D34AB44A29DQ35438629-E57CA8CB-BCA6-48E3-99BF-661B8F48D497Q36578769-F22B3BBF-3996-40E8-8737-88658B4DEA16Q36794401-E74B6346-FABA-4C5B-81F3-52B28EF0B9B8Q36840105-C7DC7241-E052-488A-8A86-E9C9A7AE1ECCQ37766297-38E5A4A6-F00C-4706-B955-E28A23F997A2Q38001813-3F904BFF-A862-472A-90CB-BDD9D762C407Q38079748-C30F77BD-6BE5-4E3B-91B4-4C5FB4C985A1Q38623992-BCD607C5-8E8B-4C73-9889-A4F4AC49E664Q39545821-F0D9E0B2-E91F-4A00-8DDB-54A70C096467Q39741477-7B580204-14E8-4263-B01E-59E0A5924723Q39788269-A564605E-0933-46DE-B06A-62A2D49CE11CQ40880167-9251EF3D-5F82-458A-BD2D-3DBDFC2D4ADCQ41018882-006D7B3D-53DB-4E24-9918-89C6DC707493Q41119213-ABE40712-A78B-4928-83A7-30B4ABB43C52Q41278766-51EABD96-5C60-48A1-99EA-3E8762B0BD37Q41449030-A59F4D23-D01A-4322-A0CD-30624D56C149Q43653942-9503D7B7-F42F-4527-AD94-863DB6CFEA51Q43693224-B95B8FA3-5DBB-49F0-A0F9-8FAFA8646BAAQ44726413-FDB13028-82DC-47EC-A682-6B04C077A224Q44796003-961D5E50-1E06-4647-AA06-FC483BF58E0FQ48628756-456E70EB-F231-4C1F-A310-665D2A23EBDDQ50141101-73D8CEF2-8D7E-48EE-B9FC-50C92B55CE89Q50743005-5AEC4FAD-7029-4D0F-873D-C7A5138B41CDQ51055682-1B091EE5-DDA5-454A-AD01-58DCC3FF987BQ51753774-33BE677D-31E1-49FE-9D71-BDF9EF90887AQ52881400-008EEDB1-B104-4658-8E96-834D3BE9BAF0Q52889394-F997D0A2-EF6E-4ABE-9CA3-B71A402CF0D9Q53569173-96A39E27-454A-44EE-9AF7-7E43AC152E51
P2860
Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Cost effectiveness/utility ana ...... ead us to where we want to be?
@ast
Cost effectiveness/utility ana ...... ead us to where we want to be?
@en
Cost effectiveness/utility ana ...... ead us to where we want to be?
@nl
type
label
Cost effectiveness/utility ana ...... ead us to where we want to be?
@ast
Cost effectiveness/utility ana ...... ead us to where we want to be?
@en
Cost effectiveness/utility ana ...... ead us to where we want to be?
@nl
prefLabel
Cost effectiveness/utility ana ...... ead us to where we want to be?
@ast
Cost effectiveness/utility ana ...... ead us to where we want to be?
@en
Cost effectiveness/utility ana ...... ead us to where we want to be?
@nl
P1476
Cost effectiveness/utility ana ...... ead us to where we want to be?
@en
P304
P356
10.1016/0167-6296(92)90004-K
P577
1992-10-01T00:00:00Z